Stifel raised its price target on Bausch & Lomb Corp. (NYSE:BLCO) shares to $15 from $14 while retaining a Hold recommendation, the firm said on Monday.
The move followed a dry eye treatment survey Stifel conducted among 49 eye care professionals, a group that included both optometrists and ophthalmologists. The survey solicited prescriber feedback comparing Bausch & Lomb’s Miebo to Alcon’s Tryptyr.
On physician satisfaction, Miebo recorded a mean score of 1.31 on a scale ranging from -2 to +2, the highest average of the therapies included in the survey. By contrast, Tryptyr received a mean satisfaction rating of 0.87 from the same prescriber pool.
Stifel said it raised its revenue assumptions for Miebo on the basis of those survey results. The research note indicated that respondents expect Tryptyr’s market ramp to be slower than Miebo’s, a dynamic Stifel suggested could support Bausch & Lomb’s top line. The company reported $4.98 billion in revenue over the last twelve months, representing 6.2% growth.
Despite the revised Miebo outlook, Stifel maintained that consensus forecasts for Bausch & Lomb’s total revenue and EBITDA remain elevated and therefore do not justify an upgrade of the stock’s rating.
In a separate analyst action, RBC Capital raised its price target for Bausch & Lomb to $21 from $19 and kept an Outperform rating. RBC anticipates fourth-quarter 2025 revenue of $1,385 million, a figure it noted is slightly above consensus estimates of $1,384 million. The firm also projects adjusted EBITDA of $324 million, compared with the consensus of $322 million.
Separately, Stifel has reiterated a Hold rating on Bausch & Lomb with a price target of $14, citing concerns about the company’s capacity to compete effectively in several key growth markets. Together, these analyst notes offer investors updated expectations for Bausch & Lomb’s near-term financial performance alongside reminders of competitive challenges.
Contextual note - The commentary and projections described above reflect the analysts' interpretations of the survey data and financial models referenced in their respective notes.